Crystal of fused heterocyclic compound
The present invention relates to a crystal of 1-ethyl-7-methyl-3-{4-[(3-methyl-3H-imidazo[4,5-b]pyridin-2-yl)oxy]phenyl}-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one useful as a prophylactic or therapeutic agent for schizophrenia and the like, which shows an X-ray powder diffraction pattern having characteristic peaks at interplaner spacings (d) of 13.59 plus or minus 0.2 and 6.76 plus or minus 0.2 Angstroms in powder X-ray diffraction.
1. A crystal of 1-ethyl-7-methyl-3-{4-[(3-methyl-3H-imidazo[4,5-b]pyridin-2-yl)oxy]phenyl}-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one showing an X-ray powder diffraction pattern having characteristic peaks at interplaner spacings (d) of 13.59±0.2, 9.22±0.2, 7.88±0.2, 7.48±0.2, 6.76±0.2, 6.21±0.2, 6.13±0.2, 5.73±0.2, 5.24±0.2, 5.13±0.2, 4.64±0.2, 4.27±0.2, 4.16±0.2, 4.06±0.2, 3.99±0.2, 3.93±0.2, 3.79±0.2, 3.75±0.2, 3.60±0.2, 3.41±0.2, 3.16±0.2, 3.10±0.2, 3.06±0.2, 2.89±0.2, 2.83±0.2, 2.73±0.2 and 2.58±0.2 Angstroms in powder X-ray diffraction.
2. The crystal according to claim 1 , which shows an initial temperature of about 222- about 224° C. of an endothermic behavior caused by melting in DSC measurement (temperature increase rate 5° C./min).
3. A pharmaceutical composition comprising the crystal according to claim 1 , and a pharmacologically acceptable carrier.
4. A method of treating schizophrenia in a mammal, comprising administering an effective amount of the crystal according to claim 1 to the mammal.